BACKGROUND AND OBJECTIVE: To report the effect of a "no-talking" policy during intravitreal injection (IVI) on post-injection endophthalmitis. PATIENTS AND METHODS: Retrospective, comparative, consecutive case series of patients receiving IVI between Jan. 1, 2009, and Dec. 31, 2012. A 24-month "usual care" period was compared to a 24-month no-talking period, during which a strategy to further minimize speech during IVI was implemented. RESULTS: During the usual care period, 47,155 IVIs were performed, with nine culture-positive cases (0.019%), including seven due to oral pathogens (0.015%). During the no-talking period, 82,658 IVIs were performed, with eight culture-positive cases (0.010%), including two due to oral pathogens (0.002%). The no-talking policy was associated with a decreased endophthalmitis risk (P = .004), including oral pathogen-associated endophthalmitis (P = .02). CONCLUSION: This study demonstrates that a more stringent no-talking policy during IVI may reduce the risk of post-injection endophthalmitis. Copyright 2015, SLACK Incorporated.
BACKGROUND AND OBJECTIVE: To report the effect of a "no-talking" policy during intravitreal injection (IVI) on post-injection endophthalmitis. PATIENTS AND METHODS: Retrospective, comparative, consecutive case series of patients receiving IVI between Jan. 1, 2009, and Dec. 31, 2012. A 24-month "usual care" period was compared to a 24-month no-talking period, during which a strategy to further minimize speech during IVI was implemented. RESULTS: During the usual care period, 47,155 IVIs were performed, with nine culture-positive cases (0.019%), including seven due to oral pathogens (0.015%). During the no-talking period, 82,658 IVIs were performed, with eight culture-positive cases (0.010%), including two due to oral pathogens (0.002%). The no-talking policy was associated with a decreased endophthalmitis risk (P = .004), including oral pathogen-associated endophthalmitis (P = .02). CONCLUSION: This study demonstrates that a more stringent no-talking policy during IVI may reduce the risk of post-injection endophthalmitis. Copyright 2015, SLACK Incorporated.
Authors: Samir N Patel; Jason Hsu; Meera D Sivalingam; Allen Chiang; Richard S Kaiser; Sonia Mehta; Carl H Park; Carl D Regillo; Arunan Sivalingam; James F Vander; Allen C Ho; Sunir J Garg Journal: Am J Ophthalmol Date: 2020-09-02 Impact factor: 5.258
Authors: Santiago Angaramo; Janice C Law; Alexander Spyros Maris; Jonathan Edward Schmitz; Yuhan Liu; Qingxia Chen; Amy Chomsky Journal: BMJ Open Ophthalmol Date: 2021-10-05